Management of vernal keratoconjunctivitis

Area of Science:

• Ophthalmology
• Allergology
• Immunology

Background:

• Vernal keratoconjunctivitis (VKC) is a rare, chronic allergic eye condition.
• It primarily affects children and young adults, potentially leading to severe visual complications.
• VKC involves IgE and T-cell mediated inflammation with eosinophil and lymphocyte activation.

Purpose of the Study:

• To review the management strategies for Vernal keratoconjunctivitis.
• To evaluate the efficacy and safety of immunomodulators, specifically topical cyclosporine A, in VKC treatment.

Main Methods:

• Literature review of VKC pathophysiology and treatment options.
• Analysis of studies investigating topical ocular immunomodulators for VKC.
• Assessment of clinical outcomes and side effects associated with cyclosporine A therapy.

Main Results:

• Mast cell stabilizers and antihistamines are effective for mild to moderate VKC.
• Topical steroids serve as rescue medication for severe inflammation.
• Topical cyclosporine A demonstrates long-term efficacy in improving VKC signs and symptoms with minimal side effects.

Conclusions:

• VKC management requires a comprehensive approach considering disease chronicity and severity.
• Topical cyclosporine A is a valuable therapeutic option for long-term control of Vernal keratoconjunctivitis.
• Patient and parent education regarding the chronic nature and potential complications of VKC is crucial.